Pregnant woman with heroin dependence: detox on demand versus opioid agonist treatment
A 29-year-old woman at 20 weeks of pregnancy is referred from the antenatal clinic with rhinorrhoea, piloerection, dilated pupils, yawning and abdominal cramps. She smokes heroin, roughly 1 g a day, and has had three previous inpatient detoxifications in the last four years, each followed by relapse within weeks. She has no fixed address, and her partner also uses. She booked antenatal care at 16 weeks and then defaulted. She wants to be drug free before the baby is born and asks for a supervised seven-day detoxification. The obstetric team supports this and says substitution merely trades one addiction for another. The only opioid substitution service in the district provides methadone with a six-week waiting list; buprenorphine maintenance is not available locally and the nearest alternative programme is 140 km away.
1. What do you recommend, and what is the evidence and reasoning you would present to her and to the obstetric team?
Read the worked answer
Recommend opioid agonist treatment, not a fourth detoxification. The reasoning is prognostic rather than ideological: three completed detoxifications with rapid relapse is strong evidence that a seven-day withdrawal will end in return to illicit heroin of unknown potency, with overdose risk, chaotic antenatal attendance, injecting risk and repeated withdrawal. Repeated cycles of withdrawal and relapse are associated with fetal loss and preterm labour.
International guidance (WHO and NICE) is that opioid dependence in pregnancy is a treatable medical condition and that methadone or buprenorphine maintenance, with psychosocial support and good antenatal care, gives better maternal and neonatal outcomes than detoxification. Explain to her, without moralising, that being on a stable supervised dose is not being high, it is being stable, and that it protects the fetus from repeated withdrawal.
With the obstetric team, use outcomes rather than values: agonist treatment reduces illicit use, overdose death, blood-borne virus transmission, preterm birth and length of neonatal stay. If she still wants to reduce, that is a later conversation at a stable dose, not in the second trimester with a six-week wait.
2. The service cannot see her for six weeks. How do you advocate, and what do you put in place in the meantime?
Read the worked answer
Frame the request in the language the system acts on: maternal death, neonatal abstinence syndrome, preterm delivery, hospital bed days and legal risk. Pregnant women are a recognised priority group in most substitution programmes; a six-week wait is a service failure, not a clinical answer.
Concrete steps on the same day: telephone the substitution programme's medical officer and ask for priority assessment, documenting who you spoke to; send a short written referral copied to the programme director and the provincial psychiatrist; bring in the obstetrician, neonatologist and medical social worker for a joint plan; involve the public health midwife and MOH for home follow-up and partner engagement. Ask the anaesthetist and physician to co-sign the urgency if needed.
Interim: do not leave her with nothing. Admit under the obstetric team for symptom-triggered treatment with a documented plan to transfer directly into maintenance, arrange daily supervised contact through the clinic, treat the withdrawal symptoms, screen for HIV, hepatitis and syphilis, and address housing, partner use, contraception and violence risk. If the wait truly cannot be shortened, put the transfer date in writing and give her a named contact, because an unplanned discharge is when she will be lost.
3. What neonatal and postpartum planning would you set in motion now, at 20 weeks?
Read the worked answer
Start early, because the neonatal team needs to plan and because the patient should not experience the plan as a threat.
Neonatal: a pre-birth planning meeting with her, the midwife, neonatologist, social worker and you. Agreement that the baby will be observed for 72 to 96 hours post-delivery with a standard abstinence scoring tool, that supportive care comes first (rooming-in, swaddling, small frequent feeds, low stimulation), and that morphine is used only if scoring thresholds are met. Breastfeeding is generally encouraged on a stable methadone or buprenorphine dose unless there is another contraindication.
Postpartum: maintain the same agonist dose, since dose reduction in the third trimester or immediately after delivery risks relapse; contraception advice; relapse-prevention plan and continued psychosocial support; warn her that postpartum is a high-risk period and give her a crisis contact.
Safeguarding: a referral to child protection services is a risk assessment, not a punishment, and should be framed that way to her, with the criteria for concern explained in advance. Involving her in the plan is the single strongest predictor of her staying engaged.